
Keywords: CYD-TDV; recombinant, live, attenuated, tetravalent dengue vaccine; DENV; dengue virus; IgG; immunoglobulin G; DF; dengue fever; DFC; complicated dengue fever; DHF; dengue hemorrhagic fever; NS1; dengue non-structural protein 1; EC50; half maximal effecti